Cystadenocarcinoma, Mucinous is a type of cancer that starts in the lining of a cyst, often in the ovary. It's a malignant tumor, meaning it can grow and spread. The name 'mucinous' refers to the type of cells that make up the cyst lining.
Every report comes from a Lived member, sent anonymously.
Have you had Debulking Surgery for Mucinous Cystadenocarcinoma?
Mucinous cystadenocarcinoma is a cancer that forms cyst-like tumors filled with thick, mucus-like fluid. It most often starts in an ovary, where doctors usually call it mucinous ovarian carcinoma. It is a rare type of epithelial ovarian cancer, the group that begins in the cells covering the ovary, and accounts for roughly 3 to 5 percent of those cancers. The tumor typically grows in one ovary and can become very large before it is found. Because it takes up space in the belly, the first signs are often a swollen abdomen, pain or a feeling of pressure, rather than anything specific to the ovary. Compared with the more common types of ovarian cancer, it tends to affect younger women and is usually found while it is still confined to the ovary, which makes a real difference to the outlook. Two look-alikes matter. A mucinous borderline tumor has similar cells but has not invaded the surrounding tissue, so it behaves much less aggressively. And a mucus-producing cancer from the digestive tract, such as the appendix or colon, can spread to the ovary and look almost identical. Less commonly, a mucinous cystadenocarcinoma arises in another organ, such as the pancreas; this page describes the ovarian form.
Researchers do not know exactly why this cancer develops. Many of these tumors carry changes in a gene called KRAS, which helps control cell growth, and about a quarter have extra copies of HER2, a gene that drives cell growth. These findings help explain how the cancer behaves and are the basis for some newer treatments being studied. Unlike some other ovarian cancers, mucinous carcinoma is not linked to inherited BRCA1 or BRCA2 gene changes, so a family history of breast and ovarian cancer does not carry the same weight here. Smoking is associated with a higher risk of mucinous ovarian tumors, although most of that extra risk is in borderline tumors rather than true carcinomas. No known factor means a particular person will develop it.
Evaluation usually starts with a pelvic exam and imaging. Ultrasound through the abdomen or vagina shows the size and structure of the mass, and CT or MRI helps map it and plan surgery. Blood tests for tumor markers (CA-125, CA19-9 and CEA, proteins that some tumors release into the blood) can add information, but none of them confirms or rules out this cancer. CA-125, the marker most often used for ovarian cancer, is raised less often and less strongly in mucinous tumors. The diagnosis is made when a pathologist examines the tumor under a microscope, usually after it has been removed in surgery. A key part of that work is deciding whether the tumor truly began in the ovary or spread there from the digestive tract. Special stains on the tissue help with this, and when the tumor is advanced or imaging points elsewhere, doctors may examine the stomach and bowel with an endoscope. This step matters because many tumors once labeled mucinous ovarian cancer were later found to be digestive cancers, which are treated differently.
Surgery is the main treatment. For most people it means removing both ovaries and fallopian tubes, the uterus and the omentum (a fatty layer that hangs in front of the bowel), along with any visible tumor. The surgeon also takes fluid and tissue samples from the abdomen to stage the cancer, meaning to find out exactly how far it has spread. Staging matters: in about 1 in 11 people whose cancer looked confined to one ovary, surgery found it had spread further. The appendix is usually removed only if it looks abnormal. How much more surgery is needed depends partly on the tumor's growth pattern. In the expansile pattern the cancer pushes outward in a contained way and rarely reaches the lymph nodes; in the infiltrative pattern it invades more destructively and spreads to nodes more often, so lymph node removal is more likely to be considered. For a younger person with an early tumor confined to one ovary, especially the expansile type, fertility-sparing surgery that keeps the uterus and the other ovary can be a reasonable choice, and many people who try to conceive afterward do so. It is less certain for infiltrative or more advanced tumors, and it depends on thorough staging. This cancer responds less well to the standard ovarian cancer chemotherapy (carboplatin and paclitaxel) than other types do. For early-stage disease, whether chemotherapy after surgery helps is debated; it is more often considered for higher-risk features such as an infiltrative pattern or a high-grade tumor (one whose cells look very abnormal and likely to grow quickly). For advanced disease, removing as much tumor as possible is the most important step. Drugs aimed at HER2 or at the KRAS pathway are being studied for tumors with those changes, but they are not yet proven for this cancer specifically. One HER2-targeted drug, trastuzumab deruxtecan (Enhertu), is approved for advanced solid tumors of any origin with high HER2 levels after earlier treatment, which is one reason tumor testing can matter. Clinical trials are also an option worth asking about.
Most people are diagnosed at an early stage. When the cancer is found while still confined to the ovary, the outlook is good: more than 90 percent are alive five years later, and many need surgery alone. The picture is different when the cancer has already spread through the abdomen at diagnosis. Because it responds poorly to standard chemotherapy, advanced mucinous carcinoma has a worse outlook than advanced cases of the more common ovarian cancer types, and treatment decisions are often individualized. Because the disease is rare, care at a center with gynecologic oncology experience and expert pathology review can help with both the diagnosis and the plan. Recovery from the operation takes time. Most people stay in the hospital for about 3 to 7 days and return to their usual activities within 4 to 6 weeks. If both ovaries are removed before menopause, menopause begins right away and pregnancy is no longer possible. The loss of the ovaries' hormones can bring hot flashes, trouble sleeping, mood changes and vaginal dryness, and over the longer term it can thin the bones. These effects can be treated, so they are worth raising with the care team, including whether hormone-based treatment is suitable after this cancer. Chemotherapy, when it is used, adds its own side effects, such as tiredness, nausea and a higher risk of infection, which usually ease after treatment ends. After treatment, regular follow-up visits with the cancer team check for any return of the cancer. Recurrence is less common after an early expansile tumor than after an infiltrative one, so the follow-up plan is often tailored to the tumor type and stage.
See a clinician if you have abdominal or pelvic pain, pressure or swelling, feel full quickly, or need to urinate more often, and these continue rather than come and go. A pelvic lump or a belly that keeps growing larger also deserves prompt assessment. If you have been treated for this cancer, contact your cancer team about new or returning abdominal swelling, pain or changes in bowel habits, rather than waiting for the next scheduled visit.
Last reviewed • Oct 2026
Educational content, not medical advice.
Share what living with Mucinous Cystadenocarcinoma is like, what's helped you, or ask the community a question.